An Update on the Management of Severe Cutaneous Drug Hypersensitivity Reactions

dc.authorid0000-0003-1999-6496
dc.contributor.authorGelincik, Asli
dc.contributor.authorCavkaytar, Özlem
dc.contributor.authorKuyucu, Semanur
dc.date.accessioned2025-05-10T19:35:40Z
dc.date.issued2019
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractSevere cutaneous drug hypersensitivity reactions involve of different mechanisms, some of which are life-threatening, such as Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis, generalized bullous fixed drug eruptions, serum sickness and serum sickness-like reaction and drug-induced vasculitis. These reactions may have substantial morbidity and mortality. in the past years, successive studies have provided new evidence regarding the pathogenesis of some of these severe reactions and revealed that underlying mechanisms are highly variable. Since these reactions have unique presentations and distinct pathomechanisms, the treatment methods and response rates might be different among various entities. Although supportive and local therapies are sufficient in some of these reactions, targeted immunosuppressive treatments and even mechanistic therapies such as plasmapheresis may be required in severe ones. However, there is still insufficient evidence to support the best treatment options for these patients since number of patients and large-scale studies are limited. In this review, conventional and new treatment options for severe cutaneous drug hypersensitivity reactions are presented in detail in order to provide the contemporary approaches to lessen the morbidity and mortality relevant to these severe iatrogenic diseases.
dc.identifier.doi10.2174/1381612825666191106115556
dc.identifier.endpage3901
dc.identifier.issn1381-6128
dc.identifier.issn1873-4286
dc.identifier.issue36
dc.identifier.pmid31692425
dc.identifier.scopus2-s2.0-85077174457
dc.identifier.scopusqualityQ2
dc.identifier.startpage3881
dc.identifier.urihttps://doi.org/10.2174/1381612825666191106115556
dc.identifier.urihttps://hdl.handle.net/20.500.14730/8924
dc.identifier.volume25
dc.identifier.wosWOS:000502546500008
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherBentham Science Publ Ltd
dc.relation.ispartofCurrent Pharmaceutical Design
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.subjectSevere cutaneous drug hypersensitivity
dc.subjectStevens-Johnson syndrome/toxic epidermal necrolysis
dc.subjectdrug reaction with eosinophilia and systemic symptoms
dc.subjectacute generalized exanthematous pustulosis
dc.subjectgeneralized bullous fixed drug eruptions
dc.subjectserum sickness and serum sickness-like reaction
dc.subjectdrug-induced vasculitis
dc.subjectmanagement
dc.subjectcorticosteroids
dc.subjectintravenous immunoglobulin
dc.subjecttreatment
dc.titleAn Update on the Management of Severe Cutaneous Drug Hypersensitivity Reactions
dc.typeReview

Dosyalar